Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nasdaq

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Feb 14, 2021 9:21am

167 Views

Post# 32564196

RE:RE:RE:RE:RE:RE:RE:RE:Nasdaq

Here are two more.
Any concerns that Dan has stated that complete sale (M&A) is less likely than partnerships?
I'd like to see Antibe acquired before PH3 results to reduce risk. My main concern is otenaproxesul has not been dosed in humans for more than weeks. Understand it should follow normal NSAID profile but it is still a risk.

8. AbbVie – $33.26bn

9. Takeda – $30.52bn

Top ten pharma companies in 2020
https://www.pharmaceutical-technology.com/features/top-ten-pharma-companies-in-2020/

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver